The patient received continuous intravenous injection of
nicardipine and was administered 6.25 mg captopril, 5 mg amlodipine, and 4 mg benidipine.
Postoperative hypertension: a prospective, placebo-controlled, randomized, double-blind trial, with intravenous
nicardipine hydrochloride.
These include Beta-blockers like Atenolol, Esmolol, [4] calcium channel blocker, [5] [[alpha].sub.2]-adrenergic receptors agonists--clonidine, [6] dexmedetomidine [7] Opioids-Fentanyl, Remifentanil; Vasodilators-Nitroglycerin,
Nicardipine. Many clinical trials on healthy individuals have shown that [[alpha].sub.2]-adrenergic receptor agonists, magnesium sulphate (8) are also effective in controlling these hemodynamic variations.
The patient had a history of high blood pressure, treated with perindopril and
nicardipine, and diabetes mellitus, inadequately controlled (hemoglobin A1c 7.7%) with metformin and sitagliptin.
[15] The recommended intravenous drugs include esmolol, hydralazine, labetalol,
nicardipine and sodium nitroprusside.
Nicardipine, a calcium channel blocker, was the first-line antihypertensive medication used and was carefully titrated to gradually lower the mean arterial blood pressure (BP) and mitigate abrupt variations of maternal BP.
Table Examples of medications that are >90% protein-bound (not inclusive) Category Medication(s) Antibiotics Ceftriaxone, doxycycline, ertapenem Antidepressants Duloxetine, fluoxetine, nortriptyline, sertraline Antipsychotics Chlorpromazine, clozapine, haloperidol Anxiolytics Chlordiazepoxide, diazepam, lorazepam Cardiac Amiodarone, bumetanide, furosemlde,
nicardipine, verapamil, warfarin Chemotherapy Paclitaxel, tamoxifen Diabetes Glipizide Pain Bupivacaine, buprenorphine, ibuprofen Seizure Phenytoin, valproic acid Source: Reference 1
Drug products that outsourcing facilities compound using bulk drug substances on the 503B Bulks List qualify for certain exemptions from the Federal Food, Drug, and Cosmetic Act provided certain conditions are met." The FDA identified three bulk drug substances that it has considered and is proposing not to include on the list: bumetanide,
nicardipine hydrochloride, and vasopressin.
As for the mechanisms for SO[sub]2 vasorelaxation, people found that the vasodilatory effects of SO[sub]2 were blocked by
nicardipine, a calcium channel blocker, and glyburide, a K[sub]ATP channel blocker,[22],[23],[24],[25] which suggests an involvement of calcium channels and K[sub]ATP channel in vasorelaxation.